On Rare Disease Day 2023 RemeGen Highlights Its Social Responsibility and Rare Disease Advocacy
YANTAI, China, Feb. 28, 2023 /PRNewswire/ -- RemeGen Co., Ltd.
RemeGen's RC118 for Injection Targeting Claudin 18.2 in Patients with Gastric and Pancreatic Cancers Granted Two Orphan Drug Designations by U.S. FDA
YANTAI, China, Dec. 13, 2022 /PRNewswire/ -- RemeGen Co., Ltd.
RemeGen's Disitamab Vedotin Achieves First-Line Treatment Recommendation Status for Advanced Urothelial Cancer in Updated 2022 CSCO Guidelines
YANTAI, China, Nov. 17, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a Chinese commercial-stage biotechnology company, announced onNovember 5 that the Company's self-developed novel antibody-drug conjugate (ADC) Disitamab Vedotin (RC48) has been offi...
RemeGen Releases Phase II Clinical Study Data for Treatment of Myasthenia Gravis in Chinese Patients
YANTAI, China, Nov.1, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, recently released data from the Phase II clinical study of its proprietary novel fusion protein Telitacicept for the treatment of myasthenia ...
RemeGen Receives Orphan Drug Designation from FDA for Telitacicept for the Treatment of Myasthenia Gravis
YANTAI, China, Oct. 13, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation (ODD) for its proprietary novel fusion prote...
RemeGen Announces Preliminary Results of Phase III Confirmatory Study of Telitacicept for Treatment of Systemic Lupus Erythematosus (SLE) in China
YANTAI, China, Sept. 19, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, recently announced the preliminary results of the Phase III confirmatory study of its proprietary novel fusion protein Telitacicept for th...
Biotech Company RemeGen Commemorates International Self-Care Day with Health Initiatives
YANTAI, China, July 25, 2022 /PRNewswire/ -- The 24th of July marks International Self Care Day, highlighting self-care as an essential component of wellness. On this special day, RemeGen Co., Ltd. (9995.HK, SHA: 688331), a commercial-stage biotechnology company, advocates an active and healthy ...
RemeGen to Present Three Studies on Disitamab Vedotin at 2022 ASCO Annual Meeting
YANTAI, China, May 23, 2022 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK, SHA: 688331), a commercial-stage biotechnology company, today announced that three abstracts for disitamab vedotin (RC48) have been selected for poster discussions by the 2022 American Society of Clinical Oncology (ASCO) Ann...
RemeGen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome
YANTAI, China, Jan. 26, 2022 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, recently announced positive results from the completion of its Phase II trial inChina for Telitacicept in the treatment of primary Sjögren's syndrome ("pSS"). A total of 42 patient...
RemeGen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome
YANTAI, China, Jan. 24, 2022 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, recently announced positive results from the completion of its Phase II trial inChina for Telitacicept in the treatment of primary Sjögren's syndrome ("pSS"). A total of 42 patient...
RemeGen Reiterates Commitment to Its Battle Against Autoimmune Disease on World Strengthened Immunity Day 2021
YANTAI, China, Dec. 15, 2021 /PRNewswire/ -- To celebrate World Strengthened Immunity Day, RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, reiterated its commitment to discovering, developing, and producing best-in-class biological drugs for autoimmune diseases, to create c...
RemeGen's Telitacicept and Disitamab Vedotin Enter China's National Reimbursement Drug List for SLE and Gastric Cancer Treatment
YANTAI, China, Dec. 3, 2021 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, today announced that two of its innovative drugs, a dual-targeted TACI-Fc fusion protein, Telitacicept (RC18) for treating systemic lupus erythematosus (SLE) and a novel antibody-dru...
